The Off-Label Use of Selective Serotonin Reuptake Inhibitors for Sexual Behavior Management: Risks and Considerations

The document reviews the off-label use of selective serotonin reuptake inhibitors (SSRIs) for managing inappropriate sexual behaviors, particularly in geriatric patients with dementia, due to their safer profile compared to antipsychotics. However, there are no official guidelines for this use, and the risk of post-SSRI sexual dysfunction (PSSD) is a significant concern, as it can be severe and long-lasting. The review emphasizes the need for high-quality clinical trials, as current literature is largely based on case reports and theoretical discussions. SSRIs are believed to cause sexual dysfunction by affecting serotonin receptors and inhibiting dopaminergic pathways. The document highlights the importance of ethical considerations, informed consent, and non-pharmaceutical interventions, especially in populations with limited decision-making capacity. Further research is needed to establish guidelines and understand the long-term effects of SSRIs, particularly in pediatric populations where they may impact sexual motivation later in life.